Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeaStar Medical HoldingICU +0.27%32 EV-to-FCF is -0.44 as of Jul. 27, 2026. GuruFocus rates ICU with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 343 Biotechnology companies, SeaStar Medical Holding ranks worse than 291544.9% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SeaStar Medical Holding's Enterprise Value is $6.05 Mil.
SeaStar Medical Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-13.71 Mil. Therefore, SeaStar Medical Holding's EV-to-FCF for today is -0.44.
The historical rank and industry rank for SeaStar Medical Holding's EV-to-FCF or its related term are showing as below:
ICU'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.98 Med: -0.38 Max: 0.51
Current: -0.44
During the past 6 years, the highest EV-to-FCF of SeaStar Medical Holding was 0.51. The lowest was -0.98. And the median was -0.38.
ICU's EV-to-FCF is ranked worse than 100% of 343
companies
in the Biotechnology industry
Industry Median: 14.7
vs ICU: -0.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SeaStar Medical Holding (NAS:ICU) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SeaStar Medical Holding's PE Ratio (TTM) for today is calculated as:
SeaStar Medical Holding's share price for today is $3.77.
SeaStar Medical Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.800.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SeaStar Medical Holding's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SeaStar Medical Holding EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where SeaStar Medical Holding's EV-to-FCF falls into.
SeaStar Medical Holding's current Enterprise Value is $6.05 Mil.
SeaStar Medical Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SeaStar Medical Holding (ICU) has a EV-to-FCF of -0.44 as of Jul. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on SeaStar Medical Holding and its competitors. According to the industry distribution chart, SeaStar Medical Holding ranks #999999 out of 343 companies in the Biotechnology industry.
Is SeaStar Medical Holding's EV-to-FCF too high?
SeaStar Medical Holding's current EV-to-FCF is -0.44. Based on the distribution chart, SeaStar Medical Holding ranks #999999 out of 343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SeaStar Medical Holding has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's EV-to-FCF compare to TPST and OSRH?
According to the Biotechnology industry distribution chart, SeaStar Medical Holding ranks #999999 out of 343 companies for EV-to-FCF. This places SeaStar Medical Holding in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on SeaStar Medical Holding and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SeaStar Medical Holding's current EV-to-FCF is -0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current EV-to-FCF of -0.44. The current EV-to-FCF is -0.44. SeaStar Medical Holding's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current EV-to-FCF is -0.44 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
32GF Score
Get the complete analysis for ICU
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICU has been successfully added to your 
